ChemoCentryx, Inc. (NASDAQ:CCXI) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On March9, 2018, ChemoCentryx, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December31, 2017. A copy of this press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
|Item 2.02||Financial Statements and Exhibits.|
Press Release, dated March9, 2018
ChemoCentryx, Inc. ExhibitEX-99.1 2 d463537dex991.htm EXHIBIT 99.1 Exhibit 99.1 Exhibit 99.1 ChemoCentryx Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights Phase III ADVOCATE trial of avacopan in treatment of ANCA vasculitis nears 75% of patient enrollment target as European Medicine Agency continues review process of Conditional Marketing Authorization application Strengthened balance sheet with up to $100 million in new capital commitments; Company reports $82.5 million in 2017 partnership revenue Clinical trials underway in C3 Glomerulopathy (C3G) and Focal Segmental Glomerulosclerosis (FSGS) to support registration Announces plans to initiate the clinical development of avacopan in Hidradenitis Suppurativa (HS) Conference call today at 8:30 a.m. Eastern Time MOUNTAIN VIEW,…To view the full exhibit click
About ChemoCentryx, Inc. (NASDAQ:CCXI)
ChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company’s pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.